Implementation and Effectiveness Trial of HN-STAR
NCT04208490 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 357
Last updated 2026-04-15
Summary
People who have been treated for head and neck cancer (HNC survivors) can experience serious consequences from their cancer and its treatment, ongoing risks of new cancers, and other unrelated illnesses. These concerns pose challenges to the provision of comprehensive care to HNC survivors. We created HN-STAR to facilitate and tailor the ongoing care of HNC survivors. Survivors use HN-STAR on a computer or tablet to answer questions about symptoms and health concerns before a routine visit with a cancer care provider. During the clinic visit, the provider uses HN-STAR to see evidence-based recommendations for managing each concern reported by the survivor. The provider and survivor discuss recommendations and select appropriate actions (e.g., testing, referrals, prescriptions, self-management). HN-STAR produces a survivorship care plan that includes all reported concerns and the actions selected in clinic. The survivorship care plan is given to the survivor and the primary care provider. Three months, six months, and nine months later, the survivor uses HN-STAR from home (or clinic) to report their concerns again, and a new survivorship care plan is created each time.
Our trial randomizes 20-36 oncology practices from the National Community Oncology Research Program to use HN-STAR or provide usual care to 298-400 recent survivors of head and neck cancer. We hypothesize that survivors in the HN-STAR arm will have greater improvement in patient-centered outcomes (including cancer-related well-being, symptoms, and patient activation) over one year compared to survivors in the usual care arm, measured by surveys at baseline and one year later. We also hypothesize that survivors in the HN-STAR arm will be more likely to receive care that is aligned with evidence-based recommendations during the year of the study than survivors in the usual care arm. Our final aim investigates the implementation of HN-STAR in clinical practice, using interviews and surveys of survivors, providers, and other clinic staff to understand the feasibility, acceptability, appropriateness, and other aspects of providing survivorship care to head and neck cancer survivors.
Conditions
Interventions
- OTHER
-
HN-STAR Intervention
The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
collaborator OTHER -
Wake Forest University Health Sciences
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-23
- Primary Completion
- 2026-06-30
- Completion
- 2027-06-30
Countries
- United States
Study Locations
More Related Trials
-
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
NCT03010150 ·Status: RECRUITING
-
Immunonutrition Supplementation in Head and Neck Cancer Patients Undergoing Cancer Treatment Study
NCT05526040 ·Status: UNKNOWN ·Phase: NA
-
H&N Cancer; Survivorship and Late Effects
NCT04758026 ·Status: COMPLETED
-
Studying Survivorship Care Plans in Head and Neck Cancer
NCT03106090 ·Status: TERMINATED ·Phase: NA
-
Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
NCT04098458 ·Status: COMPLETED ·Phase: NA
-
Nasopharyngeal Carcinoma Post IMRT
NCT02597426 ·Status: ACTIVE_NOT_RECRUITING
-
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
NCT00009841 ·Status: COMPLETED ·Phase: PHASE1
-
Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC
NCT02047201 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT00494182 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx
NCT00004164 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer
NCT02965001 ·Status: COMPLETED ·Phase: PHASE2
-
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma
NCT00855881 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
NCT06223568 ·Status: RECRUITING ·Phase: PHASE2
-
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00024089 ·Status: COMPLETED ·Phase: PHASE2
-
Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NCT02135042 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma (neoHNSCC)
NCT06011993 ·Status: UNKNOWN
-
Phase II Trial Evaluating Elimination of Radiation Therapy
NCT00593840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT03422536 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
NCT06957938 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer
NCT01645748 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer
NCT04666428 ·Status: COMPLETED
-
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
NCT04900623 ·Status: RECRUITING ·Phase: PHASE2
-
The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas
NCT05187091 ·Status: RECRUITING ·Phase: PHASE3
-
Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
NCT05294900 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC
NCT05516589 ·Status: COMPLETED ·Phase: PHASE2